Gastrointestinal cancer: Targeted therapies in gastric cancer—the dawn of a new era


The international phase III REGARD study demonstrated improved overall survival with ramucirumab as second-line therapy for patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma. As a novel biological treatment, is ramucirumab also the harbinger of a new era of targeted therapies in this prevalent and highly morbid disease? 
DOI: 10.1038/nrclinonc.2013.231

1 Figure or Table


  • Presentations referencing similar topics